Press Release

United States Hereditary Angioedema Therapeutics Market to Grow with a CAGR of 7.12% through 2029

Rising awareness and improved diagnosis is expected to drive the United States Hereditary Angioedema Therapeutics Market in the forecast period.

According to TechSci Research report, “United Kingdom Regenerative Agriculture Market – By Region, Competition, Forecast and Opportunities, 2029F”, the United States Hereditary Angioedema Therapeutics Market stood at USD 846.80 million in 2023 and is anticipated to grow with a CAGR of 7.12% in the forecast period, 2025-2029. Recent years have seen significant strides in treating Hereditary Angioedema (HAE), a rare genetic disorder marked by recurrent, severe swelling in various body parts. In the United States, heightened awareness of HAE among healthcare professionals and the public has led to improved diagnosis and expanded patient populations needing treatment. Traditional therapies like C1 inhibitor replacement and bradykinin receptor antagonists, while effective, had limitations. However, recent drug developments, including subcutaneous and oral options, offer enhanced convenience, fewer side effects, and improved patient experiences. The US FDA's proactive evaluation and approval of breakthrough therapies, such as lanadelumab (Takhzyro), have revolutionized HAE management. These medications provide long-lasting prevention of attacks, reducing administration frequency and improving disease control, leading to fewer hospitalizations and better patient outcomes. 

Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "United States Hereditary Angioedema Therapeutics Market.”


The HAE therapeutics market has shifted towards a more patient-centric approach, acknowledging the specific requirements of individuals with HAE and customizing treatments to enhance their quality of life. This strategy extends beyond the creation of more convenient therapies and encompasses patient support initiatives, educational materials, and advocacy campaigns aimed at empowering patients and their families. By ensuring that patients are educated and involved in managing their condition, these endeavors are crucial for achieving sustainable long-term outcomes.

The United States Hereditary Angioedema Therapeutics Market is segmented into treatment, route of administration, end-use, regional distribution, and company. 

Based on the end use, Prophylaxis segment emerged as the dominant segment in the United States market for United States Hereditary Angioedema Therapeutics Market in 2023. This is primarily due to the increasing recognition of the importance of preventive measures in managing HAE. Prophylactic treatments aim to minimize the frequency and severity of attacks, thus improving patients' overall quality of life and reducing the need for emergency interventions. Advancements in therapeutic options, such as long-acting monoclonal antibodies, have made prophylactic regimens more attractive and feasible for patients, further driving the dominance of this segment in the market.

Based on region, Mid-west segment emerged as the dominant segment in the United States market for United States Hereditary Angioedema Therapeutics Market in 2023. This is because the region hosts a substantial patient population, including those requiring specialized HAE care, leading to a heightened demand for therapeutics. The presence of renowned treatment centers and experts in the Midwest attracts patients seeking advanced care. Several pharmaceutical companies with a focus on rare diseases, including HAE, are headquartered or have a significant presence in the Midwest. This concentration fosters research, development, and commercialization efforts, driving the market's growth in the region.


Major companies operating in United States Hereditary Angioedema Therapeutics Market are:

  • BioCryst Pharmaceuticals, Inc.
  • Ionis Pharmaceuticals, Inc.
  • Seqirus Pty Ltd. (CSL Limited)
  • Attune Pharmaceuticals, Inc.
  • Adverum Biotechnologies, Inc.
  • KalVista Pharmaceuticals, Inc.
  • Takeda Pharmaceutical Company Limited
  • Pharming Healthcare N.V.
  • Sanofi AG
  • Cipla Ltd. 

Download Free Sample Report

Customers can also request for 10% free customization on this report.


“The United States Hereditary Angioedema Therapeutics (HAE) market is primed for notable expansion in the foreseeable future. Sustained research and development endeavors are continually yielding novel therapies that boast enhanced efficacy and patient-friendliness. From advanced monoclonal antibodies to oral medications and prophylactic treatments, HAE patients now have a diverse range of options for managing their condition. The heightened awareness, early diagnosis, and genetic testing are refining the detection of HAE cases, facilitating prompt intervention and tailored treatment strategies. Embracing a patient-centered approach is increasingly prevalent, nurturing a climate of empowerment and self-care among individuals grappling with HAE” said Mr. Karan Chechi, Research Director with TechSci Research, a research-based management consulting firm.

United States Hereditary Angioedema Therapeutics Market Segmented By Treatment (C1-esterase inhibitor, Bradykinin B2 receptor antagonist, Kallikrein inhibitor, Others), By Route of Administration (Intravenous, Subcutaneous, Oral), By End-use (Prophylaxis, On-demand) Region and Competition, Opportunity, and Forecast, 2019-2029F”, has evaluated the future growth potential of United States Hereditary Angioedema Therapeutics Market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in United States Hereditary Angioedema Therapeutics Market.


TechSci Research LLC

420 Lexington Avenue, Suite 300,

New York, United States- 10170

Tel: +13322586602

Email: [email protected]               


Relevant News